Regeneron Pharmaceuticals, Inc. share price logo

Regeneron Pharmaceuticals, Inc. Share Price

NASDAQ: REGN

Large Cap

$657.89

+11.02

(+1.70%)

as on

Regeneron Pharmaceuticals, Inc. Stock Performance

as on November 8, 2025 at 2:29 am IST

  • Day's Low

    Day's High

    $640.99
    $658.21
    downward going graph

    2.57%

    Downside

    0.05%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $476.49
    $834.42
    downward going graph

    27.57%

    Downside

    26.83%

    Upside

    downward going graph

Regeneron Pharmaceuticals, Inc. share price movements today

Previous Close
$646.87
Open
$650.35
Volume
417.0K
Day's Low - High
$640.99 - $658.21
52 Week Low - High
$476.49 - $834.42

Regeneron Pharmaceuticals, Inc. Historical Returns

1 Month Return
+ 10.91 %
3 Month Return
+ 15.55 %
1 Year Return
-21.54 %
3 Year Return
-13.86 %
5 Year Return
+ 11.91 %

Regeneron Pharmaceuticals, Inc. Stock Fundamentals & Key Indicators

Check Regeneron Pharmaceuticals, Inc. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$67.7B

EPS (TTM)

43.2349

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.18%

PE Ratio (TTM)

15.43

Industry PE ratio

19.200384615384614

PEG Ratio

1.154

EBITDA

4.3B

Revenue (TTM)

14.2B

Profit Margin

32.13%

Return On Equity TTM

15.19%

Regeneron Pharmaceuticals, Inc. Stock Valuation

Track how Regeneron Pharmaceuticals, Inc. P/E has moved over time to understand its valuation trends.

Regeneron Pharmaceuticals, Inc. in the last 5 years

  • Overview

  • Trends

Lowest (8.61x)

December 31, 2021

Today (15.43x)

November 7, 2025

Industry (19.20x)

November 7, 2025

Highest (24.50x)

September 30, 2024

LowHigh

Today’s Price to Earnings Ratio: 15.43x

Regeneron Pharmaceuticals, Inc. vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Regeneron Pharmaceuticals, Inc. with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
BUY$67.7B11.91%15.4332.13%
BUY$39.6B470.1%-16.34-264.83%
BUY$57.4B236.95%1448.531.36%
BUY$105.8B88.96%29.3231.35%

Stock Returns calculator for Regeneron Pharmaceuticals, Inc. Stock including INR - Dollar returns

The Regeneron Pharmaceuticals, Inc. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Regeneron Pharmaceuticals, Inc. investment value today

Current value as on today

₹84,901

Returns

₹15,099

(-15.1%)

Returns from Regeneron Pharmaceuticals, Inc. Stock

₹20,205 (-20.21%)

Dollar Returns*

₹5,107 (+5.11%)

Analyst Recommendation on Regeneron Pharmaceuticals, Inc. Stock

Based on 34 analysts

BUY

76.47%

Buy

20.59%

Hold

2.94%

Sell

Based on 34 analysts, 76.47% of analysts recommend a 'BUY' rating for Regeneron Pharmaceuticals, Inc.. Average target price of $750.57

Regeneron Pharmaceuticals, Inc. Share Price Target

Get share price movements and forecasts by analysts on Regeneron Pharmaceuticals, Inc..

What analysts predicted

12.35%UPSIDE

Target Price

$750.57

Current Price

$657.89

Analyzed by

34 Analysts

Target

$750.57

Regeneron Pharmaceuticals, Inc. target price $750.57, a slight upside of 12.35% compared to current price of $657.89. According to 34 analysts rating.

Regeneron Pharmaceuticals, Inc. Stock’s Investor Sentiment and Interest

Investment in Regeneron Pharmaceuticals, Inc. Shares on INDmoney has dropped by -6.27% over the past 30 days, indicating reduced transactional activity.

Time period: to

Change:-6.27% versus previous 30 day period

Search interest for Regeneron Pharmaceuticals, Inc. Stock has increased by 58% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:58% versus previous 30 day period

Regeneron Pharmaceuticals, Inc. Quarterly Profit & Loss

All numbers in Millions USD

Jun 2023
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Total Revenue
3,158
3,362
3,434
3,145
3,547
3,720
3,789
3,028
3,675
3,754
Gross Profit
2,650
2,820
2,805
2,711
3,066
3,229
3,223
2,564
3,145
3,232
Operating Income
1,016
1,211
1,050
751
1,069
1,179
990
591
1,079
1,026
EBITDA
1,204
1,234
1,278
830
1,763
1,628
1,095
1,040
1,657
1,919
Interest Expense
18
17
18
16
14
13
10
8
3
19
Depreciation
103
105
113
114
120
121
126
126
135
-
Income Before Tax
1,082
1,110
1,147
700
1,628
1,493
958
905
1,518
1,763
Income Tax Expense
114
103
-12
-21
195
152
40
96
127
303
Net Income
968
1,007
1,159
722
1,432
1,340
917
808
1,391
1,460
Net Profit Margin
30.66%
29.97%
33.77%
22.96%
40.38%
36.03%
24.22%
26.70%
37.86%
38.89%

Regeneron Pharmaceuticals, Inc. Annual Profit & Loss

All numbers in Millions USD

Dec 2015
Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Total Revenue
4,103
4,860
5,872
6,710
7,863
8,497
16,071
12,172
13,117
14,202
Gross Profit
3,711
4,560
5,475
6,276
7,081
7,141
13,348
10,467
12,233
12,231
Operating Income
1,251
1,330
2,079
2,534
2,209
3,576
8,946
5,385
4,047
3,990
EBITDA
1,326
1,435
2,225
2,682
2,420
4,103
9,669
5,259
4,047
5,318
Interest Expense
14
7
25
28
30
56
57
59
73
55
Depreciation
-
-
145
148
210
235
286
341
408
482
Income Before Tax
1,225
1,329
2,078
2,553
2,429
3,810
9,325
4,858
4,199
4,779
Income Tax Expense
589
434
880
109
313
297
1,250
520
245
367
Net Income
636
895
1,198
2,444
2,115
3,513
8,075
4,338
3,953
4,412
Net Profit Margin
15.50%
18.42%
20.41%
36.42%
26.91%
41.35%
50.25%
35.64%
30.14%
31.07%

Regeneron Pharmaceuticals, Inc. Quarterly Cash Flow

All numbers in Millions USD

Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Net Income
1,007
1,159
722
1,432
1,340
917
808
1,391
1,460
Operating Cash Flow
1,114
1,089
1,512
354
1,291
1,262
1,045
1,144
1,618
Investing Cash Flow
-496
-66
-1,687
-557
-574
350
647
-1,094
-402
Financing Cash Flow
-407
-446
47
-478
-634
-1,135
-1,089
-1,128
-717
Change in Cash
210
577
-128
-681
83
477
604
-1,077
497

Regeneron Pharmaceuticals, Inc. Annual Cash Flow

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Net Income
895
1,198
2,444
2,115
3,513
8,075
4,338
3,953
4,412
Operating Cash Flow
1,485
1,307
2,195
2,430
2,618
7,081
5,014
4,594
4,420
Investing Cash Flow
-1,046
-1,005
-1,463
-2,027
-70
-5,384
-3,784
-3,185
-2,468
Financing Cash Flow
-700
-24
-77
-252
-1,970
-1,005
-1,009
-1,790
-2,200
Change in Cash
-273
277
655
150
577
690
221
-381
-248

Mutual Funds that own Regeneron Pharmaceuticals, Inc. Stock

Check out the Mutual Funds with significant holdings in Regeneron Pharmaceuticals, Inc..

Global Institutional Holdings in Regeneron Pharmaceuticals, Inc.

Funds
Holdings
Vanguard Group Inc
8.89%
BlackRock Inc
8.75%
State Street Corp
4.56%
JPMorgan Chase & Co
3.72%
Dodge & Cox
3.61%

Regeneron Pharmaceuticals, Inc. News & Key Events

  • img

    Today's Timeline - 07 November

    Fri, 06:30 PM

    -

    Dupixent shows significant clinical benefits in phase 3 studies, targeting type 2 inflammation in multiple diseases.

    Fri, 06:35 PM

    -

    Positive results from LIBERTY-AFRS-AIMS trial for Dupixent in allergic fungal rhinosinusitis presented at ACAAI meeting.

    Fri, 06:45 PM

    -

    FDA accepted priority review for Dupixent's supplemental application in allergic fungal rhinosinusitis, potentially expanding its indications.

  • img

    Today's Timeline - 07 November

    Fri, 08:26 PM

    -

    Intellia collaborates with Regeneron on nex-z for ATTR amyloidosis, sharing development costs and profits.

Insights on Regeneron Pharmaceuticals, Inc.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Regeneron Pharmaceuticals, Inc. has shown a strong upward trend in its net profit over the last three quarters. The net profit increased from $808.7 million to $1.46 billion, marking an average quarterly growth of 23.3%. This consistent growth indicates a positive financial performance for the company.

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Regeneron Pharmaceuticals, Inc. has seen positive revenue growth over the last three quarters. Their revenue increased from $3.02 billion to $3.75 billion, showing an average quarterly growth rate of 9.9%.

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 1 month, REGN stock has moved up by 14.7%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Insmed Incorporated has given 897.2% return, outperforming this stock by 911.2%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Insmed Incorporated has given 152.5% return, outperforming this stock by 174.4%

About Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988.
OrganisationRegeneron Pharmaceuticals, Inc.
Headquarters777 Old Saw Mill River Road, Tarrytown, NY, United States, 10591-6707
IndustryHealth Technology
CEODr. Leonard S. Schleifer M.D., Ph.D.
E-voting on sharesClick here to vote

Key Management of Regeneron Pharmaceuticals, Inc.

Name

Title

Mr. Christopher R. Fenimore CPA

Executive VP of Finance & CFO

Mr. Rajesh Ahuja

Senior Vice President of Quality Assurance & Operations

Ms. Melissa Lozner

Senior VP & Chief Compliance Officer

Dr. Leonard S. Schleifer M.D., Ph.D.

Co-Founder, President, CEO & Co-Chairman

Dr. George D. Yancopoulos M.D., Ph.D.

Co-Founder, President, Chief Scientific Officer & Co-Chairman

Mr. Bob McCowan

Senior VP of IT & Chief Information Officer

Mr. Ryan Crowe

Senior Vice President of Investor Relations & Strategic Analysis

Mr. Joseph J. LaRosa J.D.

Executive VP, General Counsel & Secretary

Dr. Andrew J. Murphy Ph.D.

Executive VP of Research & Co-Chief Scientific Officer

Mr. Daniel P. Van Plew

Executive VP and GM of Industrial Operations & Product Supply

FAQs

What is Regeneron Pharmaceuticals, Inc. share price today?

Regeneron Pharmaceuticals, Inc. share price today is $657.89 as on at the close of the market. Regeneron Pharmaceuticals, Inc. share today touched a day high of $658.21 and a low of $640.99.

What is the 52 week high and 52 week low for Regeneron Pharmaceuticals, Inc. share?

Regeneron Pharmaceuticals, Inc. share touched a 52 week high of $834.42 on and a 52 week low of $476.49 on . Regeneron Pharmaceuticals, Inc. stock price today i.e. is closed at $657.89,which is 21.16% down from its 52 week high and 38.07% up from its 52 week low.

What is Regeneron Pharmaceuticals, Inc.'s market capitalisation today?

Regeneron Pharmaceuticals, Inc. market capitalisation is $0.07T as on .

How to invest in Regeneron Pharmaceuticals, Inc. Stock (REGN) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Regeneron Pharmaceuticals, Inc. on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Regeneron Pharmaceuticals, Inc. Shares that will get you 0.0023 shares as per Regeneron Pharmaceuticals, Inc. share price of $657.89 per share as on November 8, 2025 at 2:29 am IST.

What is the minimum amount required to buy Regeneron Pharmaceuticals, Inc. Stock (REGN) from India?

Indian investors can start investing in Regeneron Pharmaceuticals, Inc. (REGN) shares with as little as ₹88.626 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹886.26 in Regeneron Pharmaceuticals, Inc. stock (as per the Rupee-Dollar exchange rate as on ). Based on Regeneron Pharmaceuticals, Inc. share’s latest price of $657.89 as on November 8, 2025 at 2:29 am IST, you will get 0.0152 shares of Regeneron Pharmaceuticals, Inc.. Learn more about fractional shares .

What are the returns that Regeneron Pharmaceuticals, Inc. has given to Indian investors in the last 5 years?

Regeneron Pharmaceuticals, Inc. stock has given 11.91% share price returns and 19.94% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?